Engineered Glatiramoid Peptides Emulate Glatiramer Acetate Activity in Solid Tumors
Molecular Pharmaceutics · 02.11.2026 · 23 (11) · 5596-5608
DOI: 10.1021/acs.molpharmaceut.6c00718 ↗Kurz gefasst
Fachartikel in der Zeitschrift Molecular Pharmaceutics, online erschienen am 29.09.2026. Verfasst von Michelle Oti-Bronya und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biomedical Engineering, McKelvey School of Engineering, Washington University in St. Louis, Saint Louis, Missouri63130, United States. Hauptthemen laut MEDLINE: Glatiramer Acetate, Peptides, Colonic Neoplasms. Die Arbeit nennt 48 Literaturangaben. Gefördert von: National Institute of Allergy and Infectious Diseases, Washington University in St. Louis.
Abstract (Originalsprache)
Glatiramer acetate (GA) is a heterogeneous mixture of peptides that we have previously explored as an intratumoral immunomodulator. However, its chemical complexity complicates the mechanistic interpretation and rational design. In this study, we evaluated a set of sequence-defined “glatiramoid” peptides engineered to preserve the amino acid composition while varying the primary sequence. Biophysical characterization by circular dichroism, fluorescence spectroscopy, and transmission electron microscopy revealed sequence-dependent differences in supramolecular organization without pronounced changes in the secondary structure. Treatment of murine bone marrow-derived dendritic cells with these peptides produced distinct innate cytokine and chemokine secretion profiles, suggesting that sequence order influences immune signaling outcomes in vitro. In the CT26 mouse model of colon carcinoma, intratumoral administration of selected glatiramoid peptides in combination with anti-PD-1 therapy produced tumor growth responses that were not statistically distinguishable from those of commercial GA formulations. Systemic cytokine levels measured at study termination were generally lower for the sequence-defined peptide relative to GA. Together, these findings indicate that sequence-defined glatiramoid peptides reproduce selected GA-like biophysical and immunomodulatory properties. Further studies are required to establish their mechanisms of action, intratumoral behavior, and therapeutic contribution to checkpoint blockade.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Biomedical Engineering, McKelvey School of Engineering, Washington University in St. Louis, Saint Louis, Missouri63130, United States.
- Department of Chemistry, Washington University in St. Louis, Saint Louis, Missouri63130, United States.
- Kinimmune Inc., Saint Louis, Missouri63141, United States.
ORCID-Profile: Huan Gong, Anirban Das, Cory Berkland, Jai S Rudra
Förderung
- National Institute of Allergy and Infectious Diseases
- Washington University in St. Louis
Zitieren
APA
Oti-Bronya, M., Gong, H., Das, A., Brown, E. M., Zutter, H. M., Griffin, J. D., Berkland, C., & Rudra, J. S. (2026). Engineered Glatiramoid Peptides Emulate Glatiramer Acetate Activity in Solid Tumors. Molecular Pharmaceutics, 23(11), 5596-5608. https://doi.org/10.1021/acs.molpharmaceut.6c00718
Vancouver
Oti-Bronya M, Gong H, Das A, Brown EM, Zutter HM, Griffin JD, et al. Engineered Glatiramoid Peptides Emulate Glatiramer Acetate Activity in Solid Tumors. Molecular Pharmaceutics. 2026;23(11):5596-5608. doi:10.1021/acs.molpharmaceut.6c00718
BibTeX
@article{OtiBronya2026,
author = {Oti-Bronya, Michelle and Gong, Huan and Das, Anirban and Brown, Elise M and Zutter, Henry M and Griffin, J Daniel and Berkland, Cory and Rudra, Jai S},
title = {Engineered Glatiramoid Peptides Emulate Glatiramer Acetate Activity in Solid Tumors},
journal = {Molecular Pharmaceutics},
year = {2026},
volume = {23},
number = {11},
pages = {5596--5608},
doi = {10.1021/acs.molpharmaceut.6c00718}
}
EUVIMED